Trials / Not Yet Recruiting
Not Yet RecruitingNCT06309537
Chemoreflex Sensitivity in HFpEF
Chemoreflex Sensitivity in Heart Failure With Preserved Ejection Fraction
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Istituto Auxologico Italiano · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
Patients with heart failure and a preserved left ventricular ejection fraction (HFpEF) almost invariably complain of exertional breathlessness. Abnormal cardiac hemodynamics with pulmonary congestion are believed to trigger dyspnea in this patients. However, some patients may complain of exertional breathlessness which seems to be out of proportion as compared with hemodynamic abnormalities. Chemoreflex sensitivity accounts for the ventilatory responses to a variety of chemical stimuli, including carbon dioxide produced by the organism during exercise. Chemoreflex sensitivity can be augmented in heart failure with reduced left ventricular ejection fraction, and an increased chemoreflex sensitivity has been linked to symptoms, neurohumoral activation, breathing disturbances, and adverse prognosis. However, the clinical correlates and implications of chemoreflex sensitivity in HFpEF have not been accurately studied. We aim to characterize chemoreflex sensitivity in patients with a diagnosis of HFpEF, and to correlate chemoreflex sensitivity with clinical and hemodynamic characteristics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | chemoreflex evaluation | the ventilatory response to carbon dioxide and hypoxia will be assessed in study participants |
Timeline
- Start date
- 2024-10-01
- Primary completion
- 2029-12-01
- Completion
- 2029-12-01
- First posted
- 2024-03-13
- Last updated
- 2024-03-13
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06309537. Inclusion in this directory is not an endorsement.